Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD),
Subtle changes in brain activity in the presence of both amyloid-beta and tau proteins may point to Alzheimer's disease, long ...
Scientists at the West Virginia University Rockefeller Neuroscience Institute hope to unlock the true potential of drugs designed to target Alzheimer's.
The Dutch company has created a device for the early detection of Alzheimer’s disease, and it is on its way to developing ...
Worldwide, at least 50 million people are believed to be living with a form of dementia. Alzheimer's disease is the most ...
8don MSN
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...
A diagnosis in the early stages may allow you to start treatments that can slow disease progression.
The MIND diet, which stands for Mediterranean-DASH Diet Intervention for Neurodegenerative Delay, is a hybrid of the ...
News Medical on MSN1d
Calcium channel blockers show potential to restore cerebral blood flow in Alzheimer's diseaseBlocking calcium channels in brain capillaries may enhance blood flow and alleviate early-stage Alzheimer's damage, new ...
The Healthy on MSN12h
13 Things Neurologists Do to Help Prevent Alzheimer’s DiseaseUnderstand Alzheimer's disease Alzheimer's disease is the leading cause of dementia, accounting for approximately 80% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback